原发性附睾恶性肿瘤1例报告并文献复习

目的：提高原发性附睾恶性肿瘤的诊治水平,探讨原发性附睾恶性肿瘤的组织化学特性、诊治方法及预后。方法：回顾性分析我院收治的1例原发性附睾胚胎性癌患者的发病诊治过程的临床资料并结合文献进行复习。结果：对患者行根治性右侧睾丸、附睾切除术。术后病理回报：附睾、睾丸胚胎性癌,精索未见明显侵犯。术后1年,随诊复查未见异常,至今无复发。结论：附睾恶性肿瘤无特异性,其诊断应综合病史、体检、影象学检查及术中、术后病理确定。手术是治疗附睾肿瘤的首选方法。     

早期宫颈癌患者围手术期外周血淋巴细胞数与其预后的关系

目的:探讨早期宫颈癌患者围手术期外周血淋巴细胞数与其预后之间的关系。方法:回顾性分析2006年1月至2012年12年就诊于解放军总医院,根据2009年最新宫颈癌FIGO指南诊断为Ⅰb~ⅡA期宫颈癌进行阴式宫颈癌根治术患者的临床病历资料。分析患者的围手术期淋巴细胞数和其无瘤生存期、总生存期间的关系。结果:共143例阴式早期宫颈癌根治术患者纳入研究,随访时间为6~87个月,中位随访时间为53个月。术后,宫颈癌患者外周血淋巴细胞数显著下降。术前外周血淋巴细胞数较高的患者无瘤生存期及总生存期均较外周血淋巴细胞数低于平均水平的患者显著延长(P0.05);术后第三天淋巴细胞数恢复或高于术前水平的患者无瘤生存期较术后第三天淋巴细胞数低于术前水平的患者显著延长(P0.05),但总生存期无明显差异(P0.05)。COX回归分析显示术前淋巴细胞数高于平均水平及术后第三天淋巴细胞数高于或等于术前水平的宫颈癌患者的预后相对较好。结论:术前淋巴细胞数和术后第三天淋巴细胞数的变化均可作为评估宫颈癌术后患者预后的重要参考指标。     

SPECT 对症状性颅内动脉狭窄支架成形术的疗效评价

目的:通过SPECT脑血流灌注显像,对症状性颅内动脉粥样硬化性狭窄行颅内支架成形术,进行血流动力学的疗效评价。方法:对42例症状性颅内动脉粥样硬化性狭窄(狭窄程度>50%)患者,术前通过SPECT,分为低灌注组和正常灌注组。术后3月复查SPECT,做出血流动力学的疗效评价。通过术前及术后1年mRS评分,比较两组的远期疗效。结果:低灌注组发病症状一般为缺血性卒中,正常灌注组一般为TIA(P<0.01)。低灌注组术后血流灌注较术前改善明显(P<0.01)。正常灌注组复发性TIA的发生率较低灌注组高(P<0.05)。低灌注组术前术后mRS评分有统计学差异(P<0.05)。结论:颅内支架成形术可以明确改善颅内低灌注区的血流灌注,对低灌注组术后缺血事件的预防效果好,并有改善神经功能作用。因此,存在颅内低灌注区的患者更具有颅内支架成形术的手术适应症。     

原发性肝透明细胞癌影像学及临床分析

目的:探讨原发性肝细胞癌(PCCCL)的影像学及临床病理等特点,提高对肝透明细胞癌的认识,早期确诊、早期治疗、改善预后等,以避免临床误诊,并评价PCCCL的预后比例及疗效。方法:回顾性分析了2009年至2010年我院肿瘤科收治的3例肝透明细胞癌患者的临床资料、影像学质料,以及临床治疗和随访情况。结果:3例均为男性,2例行氩氦刀靶向消融治疗,1例行CT引导下射频消融治疗,术后随访半年2例过世,1例生存。结论:原发性肝细胞癌透明细胞型早期诊断尤为重要,及时手术切除及消融治疗是取得较好疗效的关键。     

两种不同手术方式处理输尿管末端治疗上尿路肿瘤远期疗效比较

目的:比较两种不同手术方式处理输尿管末端治疗上尿路肿瘤远期疗效。方法:采用回顾性研究我科后腹腔镜肾输尿管全长切除术治疗上尿路移行细胞癌的资料,对86例上尿路肿瘤术后患者的临床资料进行分析。A组:经尿道电切输尿管口53例,电切前先电灼患侧输尿管口;B组:开放手术行输尿管末端膀胱袖套状切除33例。比较两组术后膀胱癌发生率、局部复发率、远处转移率以及生存率等指标的差异。结果:经尿道电切输尿管口组患者术后再发膀胱癌19例(31.1%);开放手术行输尿管末端膀胱袖套状切除组患者术后再发膀胱癌10例(24.4%)。两组术后再发膀胱癌率(x2=0.550,P=0.458)和局部复发率(x2=0.057,P=0.811)比较差异无统计学意义。经尿道电切输尿管口组患者术后发生远处转移8例(13.1%),开放手术行输尿管末端膀胱袖套状切除组患者术后发生远处转移3例(7.3%);两组术后远处转移率比较差异无统计学意义(x2=0.360,P=0.549)。经尿道电切输尿管口组患者因肿瘤死亡20例,中位生存时间78个月;开放手术行输尿管末端膀胱袖套状切除组患者因肿瘤死亡18例,中位生存时间75个月。两组患者术后生存率比较差异无统计学意义(x2=1.296,P=0.255)。结论:经尿道电切输尿管口与开放手术行输尿管末端膀胱袖套状切除两种手术方法处理输尿管末端治疗上尿路肿瘤远期疗效相似。     

影响肝切除术后行TACE 患者预后因素的分析

目的:对原发性肝细胞肝癌(HCC)肝部分切除术后行经肝动脉化疗栓塞(TACE)的病人和未行TACE病人影响其预后的多种因素进行分析和评价,为肝切除术后是否行TACE治疗寻找筛选条件。方法:对我院2003～2008年期间在我院肝胆外科行原发性肝细胞肝癌手术治疗221例(术后介入治疗103例,术后非介入治疗118例)患者进行全面随访了解患者的预后情况,分别对术后接受介入治疗和非介入治疗两组通过Kaplan-Meier及COX回归分析影响预后的因素,包括:年龄、性别、血清HBsAg、肿瘤直径、肿瘤大体分型、有无癌栓形成,肿瘤分期(TNM)共7项指标。结果:在1年生存期内介入治疗组中的性别、年龄、血清HBsAg、肿瘤直径、肿瘤大体分型无统计学意义(p>0.05),有无癌栓形成及肿瘤分期有意义(p<0.05);非介入组内年龄、性别、血清HBsAg无统计学意义,肿瘤直径、肿瘤大体分型、有无癌栓形成,肿瘤分期有意义;在3年生存期内介入治疗组中的以上指标无统计学意义,而非介入组在肿瘤直径、有癌栓形成及肿瘤分期方面与统计学意义。结论:对于肿瘤直径>5cm及术后病理证实为低分化的患者给予积极TACE治疗可明显提高近期生存率。     

腹腔镜与开腹胰十二指肠切除术治疗胰头癌的疗效对比及术后肿瘤早期复发的随访研究

摘要 目的：对比腹腔镜与开腹胰十二指肠切除术治疗胰头癌的疗效,并分析术后肿瘤早期复发的影响因素。方法：选择2019年3月~2020年4月期间四川大学华西空港医院普外科收治的15例及四川大学华西医院胰腺外科收治的65例共计80例胰头癌患者,根据手术方式的不同分为开腹组和微创组,例数分别为32例和48例,对比两组围术期相关临床指标、并发症发生率和随访期间的肿瘤早期复发率。采用多因素Logistic回归分析术后早期复发的影响因素。结果：微创组的手术时间长于开腹组,住院费用多于开腹组,术中出血量少于开腹组,下床活动时间、术后排气时间、开始进食时间、术后住院时间短于开腹组（P<0.05）。两组并发症发生率对比无差异（P>0.05）。两组术后肿瘤早期复发率对比差异无统计学意义（P>0.05）。单因素分析结果显示,胰头癌患者术后肿瘤早期复发与年龄、肿瘤最大直径、有无淋巴结转移、有无脉管癌栓、有无神经侵犯、术前白蛋白、术前糖类抗原125（CA125）、术前癌胚抗原（CEA）水平、术后有无放化疗有关（P<0.05）。多因素Logistic回归分析显示：淋巴结转移、脉管癌栓、神经侵犯、术后未放化疗以及术前CA125水平较高是胰头癌患者术后肿瘤早期复发的危险因素（P<0.05）。结论：相较于传统开腹手术,腹腔镜下行胰十二指肠切除术治疗胰头癌,可缩短住院时间,促进患者术后恢复,但两者间并发症发生率和术后早期复发率无显著差异。胰头癌术后肿瘤早期复发受到淋巴结转移、脉管癌栓、神经侵犯、术后放化疗、术前CA125水平等多种因素的影响。     

颅底脊索瘤的影像学诊断及治疗研究(附26例报告)(英文)

目的:探讨颅底脊索瘤的CT、MRI表现及治疗措施。方法:回顾性分析经病理证实的26例脊索瘤患者的临床资料。肿瘤位于鞍区及鼻咽部者9例,位于中颅窝者5例,位于后颅窝者8例,混合型4例。手术入路:额颞入路-翼点开颅9例,鼻内镜下经蝶入路5例,颞下、颞枕及扩大中颅窝入路8例,4例未手术行放射治疗。结果:肿瘤全切8例,大部及次全切14例,围手术期未见死亡病例。25例患者获得随访;3例于术后1年内复发,其中2例死亡,余者颅神经损伤及肢体症状均有改善。结论:脊索瘤无典型临床表现,现多可通过术前影像学检查得以诊断,少数位于特殊位置者需与垂体瘤,颅咽管瘤,三叉神经鞘瘤等鉴别;肿瘤全切较为困难,根据需要选择相应的手术入路可明显提高手术效果;放疗可作为术后辅助治疗。     

宫腔镜或宫腹腔镜联合手术治疗子宫纵隔69例疗效观察

目的:探讨宫腔镜或宫腹腔镜联合在治疗子宫纵隔中的临床疗效。方法:对69例子宫纵隔患者行宫腔镜子宫纵隔电切术(26例)或腹腔镜监视下宫腔镜纵隔切开术(43例)的临床效果进行回顾性分析。结果:69例患者均一次手术成功,手术时间为20～105 min,平均手术时间(42.3±6.8)min;术中出血10～45 ml,平均出血量为(18.2±3.2)mL;其中无子宫穿孔、水中毒、感染及大出血等并发症,随访6～33个月,自然流产率由术前的71.4%降到术后的14.8%,不孕症患者术前为39.1%明显下降至11.6%。结论:宫腔镜或宫腹腔镜联合电切术治疗子宫纵隔安全、有效,能显著改善患者的妊娠结局,提高患者的妊娠率。     

后路360°椎体切除治疗胸椎肿瘤的围手术期护理

目的:探讨后路360°椎体切除治疗胸椎肿瘤的围手术期护理方法。方法:回顾性分析2009年1月至2010年1月后路360°椎体切除治疗胸椎肿瘤的9例患者,术前做好心理护理及术前准备。术后严密监察生命体征及肢体活动、感觉功能,指导患者早期功能锻炼,预防并发症,进行出院指导、随访。结果:9例患者均顺利完成手术。随访1～15个月,平均9个月。术后除1例术前即有截瘫的患者无恢复外,其余8例脊髓功能完全恢复。9例患者无术后并发症发生,无内固定松动断裂发生。结论:对后路360°椎体切除治疗胸椎肿瘤的患者采取正确有效的围手术期护理是提高手术成功率及促进患者康复的重要措施。     

Survival among clinical stage I–III rectal cancer patients treated with different preoperative treatments: A population-based comparison

BackgroundRadical resection is regarded as the cornerstone of rectal cancer treatment. Preoperative (chemo)radiotherapy and adjuvant chemotherapy are often administered. This population-based study compares the survival in clinical stage I–III rectal cancer patients who received either preoperative radiotherapy, preoperative chemoradiotherapy or no preoperative therapy. As secondary research questions, the association of type of radical resection and adjuvant chemotherapy on survival is also investigated.MethodsPatients diagnosed between January 2006 and December 2011 with stage I–III rectal adenocarcinoma were retrieved from the Belgian Cancer Registry database. Multivariable Cox proportional hazards regression models were applied to evaluate the association of preoperative treatment, type of radical resection and use of adjuvant chemotherapy with survival, adjusting for the baseline characteristics age, gender, WHO performance status and clinical stage.ResultsA total of 5173 rectal cancer patients were identified. Preoperative treatment was as follows: none in 1354 (26.2%), radiotherapy in 797 (15.4%) and chemoradiotherapy in 3022 (58.4%) patients. The patient group who did not receive preoperative therapy or radiotherapy followed by radical resection had a lower observed survival compared to the patient group receiving preoperative chemoradiotherapy. The patient groups who underwent abdominoperineal excision and those receiving adjuvant chemotherapy had a worse observed survival compared to the patient group treated with sphincter-sparing surgery and no adjuvant therapy respectively. These effects were age-dependent. Multivariable analysis demonstrated similar findings for the observed survival conditional on surviving the first year since surgery.ConclusionIn this population-based study among clinical stage I–III rectal cancer patients treated with radical resection, a superior observed survival was noticed in the patient group receiving preoperative chemoradiotherapy compared to the patients groups receiving no or preoperative radiotherapy only, adjusting for case mix, type of radical resection and adjuvant chemotherapy. Additionally, higher adjusted observed survival was also detected for the patient groups with sphincter-sparing surgery or no adjuvant chemotherapy.     

Survival after radiation therapy for high-grade glioma

BackgroundHigh-grade gliomas (HGGs) are a heterogeneous disease group, with variable prognosis, inevitably causing deterioration of the quality of life. The estimated 2-year overall survival is 20%, despite the best trimodality treatment consisting of surgery, chemotherapy, and radiotherapy.AimTo evaluate long-term survival outcomes and factors influencing the survival of patients with high-grade gliomas treated with radiotherapy.Materials and methodsData from 47 patients diagnosed with high-grade gliomas between 2009 and 2014 and treated with three-dimensional radiotherapy (3DRT) or intensity-modulated radiotherapy (IMRT) were analyzed retrospectively.ResultsMedian survival was 16.6 months; 29 patients (62%) died before the time of analysis. IMRT was employed in 68% of cases. The mean duration of radiotherapy was 56 days, and the mean delay to the start of radiotherapy was 61.7 days (range, 27–123 days). There were no statistically significant effects of duration of radiotherapy or delay to the start of radiotherapy on patient outcomes.ConclusionsAge, total amount of gross resection, histological type, and use of adjuvant temozolomide influenced survival rate (p < 0.05). The estimated overall survival was 18 months (Kaplan–Meier estimator). Our results corroborated those reported in the literature.     

无创颅内压监测在创伤性急性弥漫性脑肿胀治疗中的临床应用研究

目的:探讨无创颅内压监测(Intracranial pressure,ICP)监测对救治创伤性急性弥漫性脑肿胀(Posttraumatic acute diffuse brains welling,PADBS)患者的辅助作用,为无创ICP检测的临床应用提供参考依据。方法:收集2011年1月至2016年1月我院神经外科收治的114例PADBS患者的临床资料进行回顾性分析,依据纳入与排除标准共取得病例组53例,对照组61例,分别给予采用无创颅内压监测和有创颅内压监测,根据患者资料进行组间比较及生存分析。结果:病例组与对照组不同分型颅内压检测值比较无统计学差异(P0.05);患者48h内进行大骨瓣开颅手术时间的生存分析,病例组中位手术时间为35.6个月,对照组中位DFS为33.5个月,两组患者检测进行手术时间的生存曲线无统计学差异(P0.05);有创ICP检测患者继发性出血率为3.2%,脑脊液感染病况为7.9%;两组患者预后情况差异并无统计学意义(P0.05)。无创ICP检测患者住院天数短于有创ICP检测患者(P0.05)。结论:无创ICP应用于PADBS治疗的临床价值与有创ICP相当,但无创ICP更便捷、创伤小,有利于对患者进行持续性检测。     

Adjuvant gamma knife surgery and image-guided,intensity-modulated radiation therapy for the treatment of sacral chordomas

AimThe aim of this study was to confirm whether patients with sacral chordoma benefit from adjuvant radiotherapy and to determine the optimal photon radiotherapy module for comprehensive treatment.BackgroundChordoma is a rare slow-growing neoplasm arisen from cellular remnants of the notochord. About 50% occur in the sacrococcygeal region. Surgical resection and adjuvant radiation therapy are recommended treatment due to the improving local control rate.Materials and methods118 patients treated by surgery and adjuvant radiotherapy from August 2003 to May 2015 were retrospectively analyzed. All patients received surgical resection after diagnosis. Among these patients, 44 were treated by exclusive surgery, and 48 were treated with adjuvant image-guided, intensity-modulated radiation therapy (IG-IMRT). In addition, 26 patients were treated with gamma knife surgery (GKS) after surgical resection. The median follow-up was 54 months for all patients. Kaplan–Meier analysis was used to calculate recurrence-free survival (RFS) overall survival (OS).ResultsPatients treated with adjuvant radiotherapy had better RFS (p = 0.014) than those treated exclusively by surgery. The patients in the IG-IMRT group exhibited better recurrence-free survival (p = 0.01) than the GKS group. Moreover, in the IG-IMRT group, patients treated by higher dose were associated with better RFS (p = 0.04). No significant difference in OS was found. No grade 3 late toxicity was found.ConclusionsWe confirmed that adjuvant radiotherapy improved RFS but not OS in sacral chordoma patients after surgery. Furthermore, favorable RFS and low adverse event rates were observed following IG-IMRT. Our results suggest that high dose IG-IMRT is an appropriate module of adjuvant radiotherapy for sacral chordoma patients.     

Adjuvant Therapy for Thymic Carcinoma – A Decade of Experience in a Taiwan National Teaching Hospital

Background

Thymic carcinomas are rare tumors for which surgical resection is the first treatment of choice. The role of adjuvant treatment after surgery is unknown because of limited available data. The present study evaluated the efficacy of post-surgery adjuvant chemotherapy or radiotherapy in patients with thymic carcinoma.

Methods

To evaluate the role of adjuvant therapy in patients with thymic carcinoma, we retrospectively reviewed the records of patients with thymic carcinoma who were diagnosed and treated between 2004 and 2014.

Results

Among 78 patients with thymic carcinoma, 30 patients received surgical resection. Progression-free survival (PFS) and overall survival (OS) were significantly longer among these patients than among patients who received other treatments (PFS: 88.4 months vs 9.1 months, p<0.001; OS: 134.9 months vs 60.9 months; p = 0.003). Patients with stage III thymic carcinoma who received surgery had a longer OS than patients who did not receive surgery (70.1 months vs 23.9 months; p = 0.017, n = 11). Among 47 patients with stage IV carcinoma, 12 patients who received an extended thymothymectomy had a longer PFS than 35 patients who did not receive surgery (18.9 months vs 8.7 months; p = 0.029). Among 30 patients (with stage I- IV carcinoma) who received primary lesion surgery, 19 patients received an R0 resection and 9 patients of the 19 patients received adjuvant radiotherapy. These patients had longer PFS (50.3 months) than 2 patients who received adjuvant chemotherapy (5.9 months) or 4 patients who received concurrent chemoradiotherapy (7.5 months) after surgery (p = 0.003).

Conclusions

Surgical resection should be considered for patients with thymic carcinoma, even for patients with locally advanced or stage IV carcinoma. Adjuvant radiotherapy resulted in a better PFS after R0 resection.     

原发性骨恶性纤维组织细胞瘤24例临床特征及预后分析

摘要 目的：总结原发性骨恶性纤维组织细胞瘤（PBMFH）的临床特征和预后。方法：回顾性分析我院2000年10月至2011年1月收治的24例PBMFH患者的术前影像学资料、诊断依据、治疗方案和随访资料。结果：24例患者全部通过术后病理确诊,穿刺准确率为75.00%.胸部X线检查结果显示：2例发现肺部转移灶,22例未发现肺部转移灶。肿瘤局部X线检查结果显示：3例出现骨质溶解性破坏,1例出现肿块影,20例表现为骨膜反应。MRI检查结果显示：4例MRI检查肿瘤局部情况时发现3例T1WI等信号、T2WI稍高信号,1例T1WI低信号、T2WI低信号。本研究中行放化疗18例,有6例（33.33%）发生转移,转移时间为6~45个月,中位转移时间为（25.30±6.24）个月,单纯手术治疗6例中有5例发生转移（83.33%）,转移发生时间为3~6月,中位转移时间为（5.00±0.24）个月。结论：PBMFH患者单纯手术出现转移多发生于术后5月,根治性手术辅以放化疗出现转移多发生于术后25月。由此可见,术前穿刺活检病理有助于疾病诊断,术后辅助化疗有助于降低PBMFH的复发率和转移率。     

Preoperative neoadjuvant chemoradiation for locally advanced gastric adenocarcinoma

Aims and BackgroundTo evaluate toxicity and the radical resection rate in gastric adenocarcinoma treated with preoperative neoadjuvant chemoradiation.Materials & Methods32 patients, 22 males and 10 females with gastric adenocarcinoma, were treated with chemoradiation and hyperthermia.ResultsThe neoadjuvant regimen was completed as planned in 19/32 (59 %) patients; in the remaining patients the intensity of chemotherapy had to be reduced because of haematological and gastrointestinal toxicity. Surgical stage was as follows: 2 patients pathologically complete response, 3 patients AJCC stage I.A, 5 patients stage I.B, 7 patients stage II, 7 patients stage III.A, 1 patient stage III.B, 7 patients stage IV. R0 resection was achieved in 19/32 (59%) patients, R1 in 2/32 (6%) patients and R2 in 11 (34%) patients. Downstaging after neoadjuvant chemoradiotherapy was achieved in 17/32 (53%) patients. At the date of evaluation (31 March 2009), 4 patients were still alive 58, 81, 86 and 98 months from the date of diagnosis. Median survival was 18 months (95% confidence interval: 13–38 months). One-year survival was 69% (95% confidence interval: 53%–85%). Four-year survival was 19% (95% C.I.: 5%–34%).ConclusionsPreoperative neoadjuvant chemoradiotherapy has acceptable toxicity, and can lead to a high rate of R0 resections.     

Chemoradiotherapy or chemotherapy as adjuvant treatment for resected gastric cancer: should we use selection criteria?

BackgroundThe management of gastric adenocarcinoma is essentially based on surgery followed by adjuvant treatment. Adjuvant chemotherapy (CT) as well as chemoradiotherapy (CTRT) have proven their effectiveness in survival outcomes compared to surgery alone. However, there is little data comparing the two adjuvant approaches. This study aimed to compare the prognosis and survival outcomes of patients with gastric adenocarcinoma operated and treated by adjuvant radio-chemotherapy or chemotherapyMaterials and methodsWe retrospectively evaluated 80 patients with locally advanced gastric cancer (LGC) who received adjuvant treatment. We compared survival outcomes and patterns of recurrence of 53 patients treated by CTRT and those of 27 patients treated by CT.ResultsAfter a median follow-up of 38.48 months, CTRT resulted in a significant improvement of the 5-year PFS (60.9% vs. 36%, p = 0.03) and the 5-year OS (55.9% vs. 33%, p = 0.015) compared to adjuvant CT. The 5-year OS was significantly increased by adjuvant CTRT (p = 0.046) in patients with lymph node metastasis, and particularly those with advanced pN stage (p = 0.0078) and high lymph node ratio (LNR) exceeding 25% (p = 0.012). Also, there was a significant improvement of the PFS of patients classified pN2–N3 (p = 0.022) with a high LNR (p = 0.018). CTRT was also associated with improved OS and PFS in patients with lymphovascular and perineural invasion (LVI and PNI) compared to chemotherapy.ConclusionThere is a particular survival benefit of adding radiotherapy to chemotherapy in patients with selected criteria such as lymph node involvement, high LNR LVI, and PNI.     

APRO家族基因在胃癌中的表达及预后意义

目的:基于大数据挖掘分析BTG/Tob抗增殖蛋白家族(anti-proliferativeprotein family,APRO)基因在胃癌组织的表达及其对胃癌患者预后的影响。方法:采用Oncomine数据库分析APRO家族6个成员在胃癌组织中的m RNA表达情况,通过Kaplan-Meier Plotter数据库进行胃癌患者总生存期的分析。结果:相比正常胃组织,BTG2在胃癌组织中呈低表达;BTG3在肠型胃癌组织中呈高表达,而在总体胃癌组织中呈低表达。BTG3低表达的患者总生存期较短;对5-氟尿嘧啶辅助化疗的胃癌患者,低表达BTG2的预后较差。结论:BTG2、BTG3的m RNA表达在胃癌和正常胃组织中有明显差异。BTG3低表达的胃癌患者预后较差;BTG2可能参与调节胃癌患者5-氟尿嘧啶治疗的敏感性。     

Adyuvant fractionated radiotherapy after resection of intracranial hemangiopericytoma

AimReview of literature and adjuvant treatment in Hemangiopericytoma after complete resection.BackgroundIntracranial hemangiopericytoma (HPC) is an uncommon malignant vascular tumor arising from mesenchymal cells with pericytic differentiation. Surgery remains the mainstay treatment, and adjuvant radiation therapy appears to be appropriate for patients with high grade tumors or incomplete resection. We present our experience and review of the literature.Materials and methodsWe describe two cases of intracranial hemangiopericytoma located in the frontal lobe of the CNS. Both patients underwent complete tumor resection followed by adjuvant fractionated radiotherapy and completed treatment without interruptions.ResultsA local recurrence was observed in one of these cases and fractionated stereotactic radiotherapy was performed. Both patients are alive and disease has been under control up to date.ConclusionThe treatment of choice for intracranial hemangiopericytoma is a complete surgical resection as long as possible. Adjuvant radiotherapy of HPC can result in increased tumor control and should be considered as an effective treatment for patients with high grade or demonstrated residual tumor in the postoperative period. Salvage treatment using limited-field fractionated radiotherapy for local recurrence treatment is considered an acceptable option.